5-MeO-AMT
5-MeO-αMT, also known as 5-methoxy-α-methyltryptamine or as α,O-dimethylserotonin, is a psychedelic drug of the tryptamine, α-alkyltryptamine, and 5-methoxytryptamine families. It is a derivative of α-methyltryptamine and an analogue of 5-MeO-DMT. The drug is said to be the most potent psychedelic of the simple indolealkylamines. It is taken orally and is used at doses of 2 to 4mg.
Use and effects
In his book TiHKAL, Alexander Shulgin lists the dose range of 5-MeO-AMT as 2.5 to 4.5mg and its duration as 12 to 18hours. However, a wider dose range of 0.5 to 15mg has also been reported.5-MeO-AMT has supposedly been sold as 4mg tablets by the street name Alpha-O and taken as a recreational drug. Since the DEA arrests of the makers of a huge percentage of the United States' LSD in 2000, 5-MeO-AMT may have occasionally been sold under the guise of LSD in liquid, sugar cube, or blotter form, though this may be due to DEA reports of finding it on sugar cubes and blotters like LSD.
Shulgin has described the effects of 5-MeO-AMT in TiHKAL.
Overdose
If misrepresented as LSD, 5-MeO-AMT can be extremely dangerous; users may take a number of "hits" of 5-MeO-AMT, assuming that it is LSD. Unlike LSD, which is very safe in overdose, 5-MeO-AMT can be very harmful or fatal. Particularly sensitive individuals can experience symptoms of overdose at dosages in the normal range — as low as 20 mg. This has led to at least a few hospitalizations and possibly more than one death. It is likely that the overdose potential of the compound is due to its sympathomimetic effects, as the side effects noted in overdose cases include cardiac arrhythmia and seizure. It also seems that oral consumption is safer than insufflation.Gloria Discerni, 18, died after overdosing on a drug initially believed to be LSD. Authorities learned months later that the drug wasn't LSD but a "designer drug" identified as 5-MeO-AMT.
Interactions
Pharmacology
Pharmacodynamics
5-MeO-AMT acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT1A, 5-HT2A, and 5-HT2B receptors, among others. Its at the serotonin 5-HT2A receptor has been found to be 2 to 8.4nM. In relation to this, it is an extremely potent agonist of the serotonin 5-HT2A receptor in vitro, showing the highest potency of any other tryptamine assessed in one study. Its potency in activating the serotonin 5-HT2A receptor was 38-fold higher than that of dimethyltryptamine and 361-fold higher than that of psilocin in the same study. It is also a highly potent agonist of the serotonin 5-HT2B receptor, with an of 4nM.Whereas tryptamine, serotonin, and αMT show potent activity as monoamine releasing agents, including of serotonin, norepinephrine, and/or dopamine, the monoamine-releasing activity of 5-methoxylated tryptamine derivatives, like 5-methoxytryptamine, 5-MeO-NMT, and 5-MeO-DMT among others, is dramatically reduced or abolished. Accordingly, whereas the values of αMT for induction of monoamine release are 22 to 68nM for serotonin, 79 to 112nM for norepinephrine, and 79 to 180nM for dopamine, the values in the case of 5-MeO-AMT are 460nM for serotonin, 8,900nM for norepinephrine, and 1,500nM for dopamine. Similarly, it is of very low potency as a monoamine reuptake inhibitor. Considering the very high potency of 5-MeO-AMT in activating the serotonin 5-HT2A receptor, its weak activities as a monoamine releasing agent and reuptake inhibitor are of questionable significance.
5-MeO-AMT is a weak monoamine oxidase A inhibitor, with an of 31,000nM. For comparison, the of AMT for MAO-A inhibition was 380nM and the values of amphetamine for MAO-A inhibition have been reported to be 11,000 to 70,000nM.
5-MeO-AMT produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and this is reversed by the serotonin 5-HT2A receptor antagonist ketanserin. It substitutes for other psychedelics such as DOM and LSD in animal drug discrimination tests, but does not substitute for entactogens like MDMA or psychostimulants like dextromethamphetamine or cocaine. In contrast to other psychedelics, 5-MeO-AMT has been found to not fully substitute for other psychedelics including DOM, LSD, and dimethyltryptamine, but did partially generalize to LSD. This is analogous to findings with 5-MeO-DMT, which has a major serotonin 5-HT2A receptor-mediated component to its discriminative stimulus properties. 5-MeO-AMT does not produce locomotor hyperactivity, behavioral sensitization, conditioned place preference, or self-administration, further indicating a lack of psychostimulant-like effects as well as misuse potential. Instead, 5-MeO-AMT produces hypolocomotion. 5-MeO-AMT is known to produce sympathomimetic effects, but these effects likely depend on serotonin 5-HT2A receptor activation rather than on monoamine release or reuptake inhibition. Other serotonergic psychedelics are also well known to produce sympathomimetic effects.